查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1951841

藥物研發市場分析及預測（至2035年）：類型、產品類型、服務、技術、應用、流程、最終用戶、研發階段

Drug Development Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, Process, End User, Stage
出版日期: | 出版商: Global Insight Services | 英文 385 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

預計藥物研發市場規模將從2024年的1,043億美元成長到2034年的1,612億美元，年複合成長率約為5%。藥物研發市場涵蓋了新藥上市的複雜流程，包括藥物發現、臨床前研究、臨床試驗和監管核准。該市場的發展動力主要來自技術進步、研發投入的增加以及對創新治療方法的需求。關鍵趨勢包括個人化醫療、生物製藥以及人工智慧在藥物發現中的應用，這些趨勢正在提升效率和成功率，為產業相關人員帶來盈利的機會。

受生物技術和個人化醫療進步的推動，藥物研發市場正經歷強勁成長。生物製劑領域成長最為迅猛，這主要得益於慢性病盛行率的上升以及對標靶治療需求的不斷成長。單株抗體和重組蛋白憑藉其高特異性和高療效，成為該領域的主要貢獻者。小分子藥物因其易於生產和廣泛的治療應用而備受青睞，仍然是成長第二快的領域。在生物製藥細分領域，基因療法和細胞療法展現出顯著的成長動能，反映出治療方向正轉向創新治療方法。免疫療法的興起，尤其是在腫瘤治療領域，標誌著人們越來越重視利用免疫系統來治療疾病。人工智慧（AI）和機器學習在藥物發現過程中的應用，進一步提高了效率並縮短了上市時間。策略夥伴關係和合作至關重要，它們能夠幫助企業獲得最尖端科技並拓展研發能力，從而在這個充滿活力的市場中建立競爭優勢。

市場區隔
類型 小分子藥物、生物製藥、疫苗、生物相似藥、基因療法、細胞療法、抗體藥物複合體、胜肽類藥物及核酸類藥物
產品 原料藥（API）、成品劑型、中間體及輔料
服務 受託研究機構(CRO)、契約製造組織 (CMO)、臨床試驗管理、法規諮詢、實驗室服務、資料管理服務
科技 高通量篩檢、生物資訊學、奈米技術、CRISPR、人工智慧與機器學習、合成生物學
應用領域 腫瘤學、心血管疾病、神經病學、感染疾病、免疫學、代謝性疾病、罕見疾病
過程 臨床前開發、臨床試驗、藥物發現、製劑開發
最終用戶 製藥公司、生技公司、研究機構、學術機構、醫院
步 藥物發現、臨床前研究、I期臨床試驗、II期臨床試驗、III期臨床試驗、IV期臨床試驗

藥物研發市場的特徵是市場環境瞬息萬變，包括市佔率分佈、定價策略和新產品上市等。大型製藥公司正利用其研發能力推出創新治療方法，以鞏固市場地位。儘管定價仍然受到生產成本和競爭壓力等因素的影響，但新產品快速上市凸顯了該行業為滿足未被滿足的醫療需求所做的努力。這種競爭環境促使各公司努力在價格可負擔性和尖端創新之間取得平衡，從而打造強大的藥物研發管線。藥物研發市場的競爭異常激烈，各公司透過對競爭對手進行比較分析來維持競爭優勢。監管的影響至關重要，遵守嚴格的指導方針是進入市場和永續性的必要條件。北美和歐洲主導監管格局，制定了影響全球營運的高標準。同時，新興市場由於監管相對寬鬆和醫療保健投資不斷增加，也提供了成長機會。在技​​術創新、策略聯盟和不斷發展的法規結構的推動下，該市場蓄勢待發，即將迎來成長。

主要趨勢和促進因素：

由於技術創新和監管環境的不斷變化，藥物研發市場正經歷顯著的變革。其中一個關鍵趨勢是將人工智慧 (AI) 和機器學習融入藥物發現過程，從而加速識別有前景的候選藥物並縮短上市時間。這項技術變革提高了效率和成本效益，吸引了來自公共和私營部門的大量投資。個人化醫療也是一個突出的趨勢，它專注於根據基因譜量身定做治療方案。這種方法有望改善患者的治療效果，並得到了基因組學和生物技術進步的支持。監管機構正擴大採用適應性核准途徑來加快創新藥物的核准流程，從而創造出更活躍的市場環境。全球慢性病盛行率的不斷上升是推動這一趨勢的主要因素，需要開發新的治療方法。此外，由於重磅生物製藥的專利到期，生物相似藥的興起也創造了盈利的機會。能夠有效掌握這些趨勢和促進因素的公司將佔據有利地位，從而充分利用對創新醫療解決方案的激增需求。

目錄

第1章執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制
  • 複合年均成長率：成長分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章 細分市場分析

  • 市場規模及預測：依類型
    • 小分子藥物
    • 生物製藥
    • 疫苗
    • 生物相似藥
    • 基因治療
    • 細胞療法
    • 抗體藥物複合體
    • 胜肽
    • 核酸藥物
  • 市場規模及預測：依產品分類
    • 原料藥（API）
    • 最終劑型
    • 中級
    • 添加劑
  • 市場規模及預測：依服務分類
    • 受託研究機構（CRO）
    • 契約製造組織（CMO）
    • 臨床試驗管理
    • 監理諮詢
    • 檢查服務
    • 資料管理服務
  • 市場規模及預測：依技術分類
    • 高通量篩檢
    • 生物資訊學
    • 奈米科技
    • CRISPR
    • 人工智慧（AI）和機器學習
    • 合成生物學
  • 市場規模及預測：依應用領域分類
    • 腫瘤學
    • 心血管疾病
    • 神經病學
    • 感染疾病
    • 免疫學
    • 代謝性疾病
    • 罕見疾病
  • 市場規模及預測：依製程分類
    • 非臨床開發
    • 臨床試驗
    • 藥物發現
    • 配方開發
  • 市場規模及預測：依最終用戶分類
    • 製藥公司
    • 生技公司
    • 研究所
    • 學術機構
    • 醫院
  • 市場規模及預測：依發展階段分類
    • 藥物發現
    • 臨床前階段
    • 第一階段
    • 第二階段
    • III期試驗
    • IV期試驗

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地區
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲地區

第6章 市場策略

  • 需求與供給差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 法規概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要企業的策略

第8章 公司簡介

  • Evotec
  • Vertex Pharmaceuticals
  • Alnylam Pharmaceuticals
  • Sarepta Therapeutics
  • Bio NTech
  • Moderna
  • Regeneron Pharmaceuticals
  • Genmab
  • Incyte
  • Ionis Pharmaceuticals
  • Bei Gene
  • Exelixis
  • Blueprint Medicines
  • argenx
  • Zai Lab
  • Ascendis Pharma
  • Galapagos
  • Cure Vac
  • Macro Genics
  • Relay Therapeutics

第9章：關於我們

簡介目錄
Product Code: GIS32279

Drug Development Market is anticipated to expand from $104.3 billion in 2024 to $161.2 billion by 2034, growing at a CAGR of approximately 5%. The Drug Development Market encompasses the intricate process of bringing new pharmaceuticals to market, including discovery, preclinical research, clinical trials, and regulatory approval. This market is driven by technological advancements, increasing R&D investments, and the demand for innovative therapies. Key trends include personalized medicine, biologics, and the integration of AI in drug discovery, which are transforming efficiencies and success rates, thus presenting lucrative opportunities for industry stakeholders.

The Drug Development Market is experiencing robust growth, propelled by advancements in biotechnology and personalized medicine. The biologics segment is the top-performing sector, driven by the increasing prevalence of chronic diseases and the demand for targeted therapies. Monoclonal antibodies and recombinant proteins are key contributors within this segment, offering high specificity and efficacy. Small molecules remain the second highest-performing segment, valued for their ease of manufacturing and broad therapeutic applications. Within the biologics sub-segment, gene therapy and cell therapy are witnessing significant momentum, reflecting the shift towards innovative treatment modalities. The rise of immunotherapies, particularly in oncology, underscores the growing emphasis on harnessing the immune system for disease treatment. The integration of artificial intelligence and machine learning in drug discovery processes is further enhancing efficiency and reducing time-to-market. Strategic partnerships and collaborations are vital, enabling access to cutting-edge technologies and expanding research capabilities, thereby fostering a competitive edge in this dynamic market.

Market Segmentation
TypeSmall Molecule Drugs, Biologics, Vaccines, Biosimilars, Gene Therapy, Cell Therapy, Antibody-Drug Conjugates, Peptides, Nucleic Acid-based Drugs
ProductActive Pharmaceutical Ingredients (APIs), Finished Dosage Forms, Intermediates, Excipients
ServicesContract Research Organizations (CROs), Contract Manufacturing Organizations (CMOs), Clinical Trial Management, Regulatory Consulting, Laboratory Services, Data Management Services
TechnologyHigh-Throughput Screening, Bioinformatics, Nanotechnology, CRISPR, AI and Machine Learning, Synthetic Biology
ApplicationOncology, Cardiovascular Diseases, Neurology, Infectious Diseases, Immunology, Metabolic Disorders, Rare Diseases
ProcessPreclinical Development, Clinical Trials, Drug Discovery, Formulation Development
End UserPharmaceutical Companies, Biotechnology Companies, Research Institutes, Academic Institutes, Hospitals
StageDiscovery, Preclinical, Phase I, Phase II, Phase III, Phase IV

The drug development market is characterized by a dynamic landscape of market share distribution, pricing strategies, and the introduction of new products. Leading pharmaceutical companies are leveraging their R&D capabilities to launch innovative therapies, thereby enhancing their market position. Pricing remains influenced by factors such as production costs and competitive pressures, while the rapid pace of new product launches underscores the sector's commitment to addressing unmet medical needs. This competitive environment fosters a robust pipeline of drugs, with companies striving to balance affordability with cutting-edge innovation. Competition in the drug development market is intense, with companies benchmarking against peers to maintain a competitive edge. Regulatory influences play a pivotal role, as compliance with stringent guidelines is essential for market entry and sustainability. North America and Europe dominate the regulatory landscape, setting high standards that impact global operations. Emerging markets, however, offer growth opportunities due to less stringent regulations and increasing healthcare investments. The market is poised for growth, driven by technological advancements, strategic partnerships, and evolving regulatory frameworks.

Geographical Overview:

The drug development market is witnessing robust growth across various regions, each presenting unique opportunities. North America remains a dominant player, driven by cutting-edge research and substantial investments in biotechnology and pharmaceuticals. The presence of leading pharmaceutical companies and a strong regulatory framework further bolster the region's growth potential. Europe follows with significant advancements in personalized medicine and a focus on sustainable drug development practices. The region's commitment to innovation and collaboration fosters a conducive environment for market expansion. In Asia Pacific, the market is rapidly evolving, spurred by increased healthcare spending and a burgeoning middle class. Countries like China and India are emerging as key contributors, benefiting from government support and a growing talent pool. Latin America and the Middle East & Africa are identified as promising growth pockets. In Latin America, the increasing prevalence of chronic diseases drives demand for innovative therapies. Meanwhile, the Middle East & Africa are investing in healthcare infrastructure, recognizing the potential of pharmaceutical advancements to enhance public health outcomes.

Global tariffs and geopolitical risks are intricately influencing the drug development market, particularly in Asia. Japan and South Korea are enhancing domestic R&D capacities to mitigate reliance on foreign APIs amid trade tensions. China is accelerating its 'Made in China 2025' initiative, focusing on biopharmaceuticals, while Taiwan leverages its robust semiconductor industry to innovate in drug manufacturing technologies. The parent market is experiencing robust growth driven by technological advancements, yet faces challenges from geopolitical instability. By 2035, the market is anticipated to evolve with a stronger emphasis on regional collaboration and supply chain resilience. Middle East conflicts, notably impacting energy prices, pose additional risks, potentially elevating operational costs across global pharmaceutical supply chains.

Key Trends and Drivers:

The drug development market is experiencing significant transformation driven by technological advancements and evolving regulatory landscapes. A key trend is the integration of artificial intelligence and machine learning in drug discovery, accelerating the identification of potential candidates and reducing time to market. This technological shift enhances efficiency and cost-effectiveness, attracting substantial investments from both public and private sectors. Personalized medicine is another prominent trend, with a focus on tailored therapies based on genetic profiles. This approach promises improved patient outcomes and is supported by advances in genomics and biotechnology. Regulatory bodies are increasingly adopting adaptive pathways to expedite the approval process for innovative drugs, fostering a more dynamic market environment. The growing prevalence of chronic diseases globally is a major driver, necessitating the development of novel therapeutics. Additionally, the rise of biosimilars presents lucrative opportunities, driven by patent expirations of blockbuster biologics. Companies that can navigate these trends and drivers effectively are well-positioned to capitalize on the burgeoning demand for innovative healthcare solutions.

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by Process
  • 2.7 Key Market Highlights by End User
  • 2.8 Key Market Highlights by Stage

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Small Molecule Drugs
    • 4.1.2 Biologics
    • 4.1.3 Vaccines
    • 4.1.4 Biosimilars
    • 4.1.5 Gene Therapy
    • 4.1.6 Cell Therapy
    • 4.1.7 Antibody-Drug Conjugates
    • 4.1.8 Peptides
    • 4.1.9 Nucleic Acid-based Drugs
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Active Pharmaceutical Ingredients (APIs)
    • 4.2.2 Finished Dosage Forms
    • 4.2.3 Intermediates
    • 4.2.4 Excipients
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Contract Research Organizations (CROs)
    • 4.3.2 Contract Manufacturing Organizations (CMOs)
    • 4.3.3 Clinical Trial Management
    • 4.3.4 Regulatory Consulting
    • 4.3.5 Laboratory Services
    • 4.3.6 Data Management Services
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 High-Throughput Screening
    • 4.4.2 Bioinformatics
    • 4.4.3 Nanotechnology
    • 4.4.4 CRISPR
    • 4.4.5 AI and Machine Learning
    • 4.4.6 Synthetic Biology
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Oncology
    • 4.5.2 Cardiovascular Diseases
    • 4.5.3 Neurology
    • 4.5.4 Infectious Diseases
    • 4.5.5 Immunology
    • 4.5.6 Metabolic Disorders
    • 4.5.7 Rare Diseases
  • 4.6 Market Size & Forecast by Process (2020-2035)
    • 4.6.1 Preclinical Development
    • 4.6.2 Clinical Trials
    • 4.6.3 Drug Discovery
    • 4.6.4 Formulation Development
  • 4.7 Market Size & Forecast by End User (2020-2035)
    • 4.7.1 Pharmaceutical Companies
    • 4.7.2 Biotechnology Companies
    • 4.7.3 Research Institutes
    • 4.7.4 Academic Institutes
    • 4.7.5 Hospitals
  • 4.8 Market Size & Forecast by Stage (2020-2035)
    • 4.8.1 Discovery
    • 4.8.2 Preclinical
    • 4.8.3 Phase I
    • 4.8.4 Phase II
    • 4.8.5 Phase III
    • 4.8.6 Phase IV

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 Process
      • 5.2.1.7 End User
      • 5.2.1.8 Stage
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 Process
      • 5.2.2.7 End User
      • 5.2.2.8 Stage
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 Process
      • 5.2.3.7 End User
      • 5.2.3.8 Stage
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 Process
      • 5.3.1.7 End User
      • 5.3.1.8 Stage
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 Process
      • 5.3.2.7 End User
      • 5.3.2.8 Stage
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 Process
      • 5.3.3.7 End User
      • 5.3.3.8 Stage
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 Process
      • 5.4.1.7 End User
      • 5.4.1.8 Stage
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 Process
      • 5.4.2.7 End User
      • 5.4.2.8 Stage
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 Process
      • 5.4.3.7 End User
      • 5.4.3.8 Stage
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 Process
      • 5.4.4.7 End User
      • 5.4.4.8 Stage
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 Process
      • 5.4.5.7 End User
      • 5.4.5.8 Stage
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 Process
      • 5.4.6.7 End User
      • 5.4.6.8 Stage
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 Process
      • 5.4.7.7 End User
      • 5.4.7.8 Stage
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 Process
      • 5.5.1.7 End User
      • 5.5.1.8 Stage
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 Process
      • 5.5.2.7 End User
      • 5.5.2.8 Stage
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 Process
      • 5.5.3.7 End User
      • 5.5.3.8 Stage
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 Process
      • 5.5.4.7 End User
      • 5.5.4.8 Stage
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 Process
      • 5.5.5.7 End User
      • 5.5.5.8 Stage
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 Process
      • 5.5.6.7 End User
      • 5.5.6.8 Stage
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 Process
      • 5.6.1.7 End User
      • 5.6.1.8 Stage
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 Process
      • 5.6.2.7 End User
      • 5.6.2.8 Stage
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 Process
      • 5.6.3.7 End User
      • 5.6.3.8 Stage
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 Process
      • 5.6.4.7 End User
      • 5.6.4.8 Stage
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 Process
      • 5.6.5.7 End User
      • 5.6.5.8 Stage

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Evotec
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Vertex Pharmaceuticals
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Alnylam Pharmaceuticals
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Sarepta Therapeutics
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Bio NTech
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Moderna
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Regeneron Pharmaceuticals
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Genmab
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Incyte
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Ionis Pharmaceuticals
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Bei Gene
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Exelixis
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Blueprint Medicines
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 argenx
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Zai Lab
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Ascendis Pharma
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Galapagos
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Cure Vac
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Macro Genics
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Relay Therapeutics
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us